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OBJECTIVE: Bacterial infections caused by antibiotic-resistant patho-
gens are a major problem for patients requiring critical care. An approach 
to combat resistance is the use of bacterial viruses known as “phage 
therapy.” This review provides a brief “clinicians guide” to phage biology 
and discusses recent applications in the context of common infections 
encountered in ICUs.
DATA SOURCES: Research articles were sourced from PubMed using 
search term combinations of “bacteriophages” or “phage therapy” with 
either “lung,” “pneumonia,” “bloodstream,” “abdominal,” “urinary tract,” or 
“burn wound.”
STUDY SELECTION: Preclinical trials using animal models, case studies 
detailing compassionate use of phage therapy in humans, and randomized 
controlled trials were included.
DATA EXTRACTION: We systematically extracted: 1) the infection set-
ting, 2) the causative bacterial pathogen and its antibiotic resistance pro-
file, 3) the nature of the phage therapeutic and how it was administered, 4) 
outcomes of the therapy, and 5) adverse events.
DATA SYNTHESIS: Phage therapy for the treatment of experimental 
infections in animal models and in cases of compassionate use in humans 
has been associated with largely positive outcomes. These findings, how-
ever, have failed to translate into positive patient outcomes in the limited 
number of randomized controlled trails that have been performed to date.
CONCLUSIONS: Widespread clinical implementation of phage therapy 
depends on success in randomized controlled trials. Additional translational 
and reverse translational studies aimed at overcoming phage resistance, 
exploiting phage-antibiotic synergies, and optimizing phage administration 
will likely improve the design and outcome of future trials.
KEY WORDS: antibiotic resistance; nosocomial infections; phage therapy
Infections due to antibiotic-resistant bacterial pathogens are a major cause of morbidity and mortality (1); the Centers for Disease Control and Prevention estimates that greater than 2.8 million antibiotic-resistant infec-
tions occur in the United States each year, and of these, 35,000 result in death 
(2). Despite the need, pharmaceutical companies continue to abandon anti-
biotic development, largely due to high costs and poor returns on investment 
(3). Given these challenges, antibiotic alternatives that kill bacteria in distinct 
ways warrant investigation. One approach is the use of bacterial viruses (bac-
teriophages/phages) known as “phage therapy (PT).” Promising results from 
laboratory studies, however, have failed to translate into improved outcomes in 
the few controlled human trials performed to date (4–7). The purpose of this 
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review is to highlight the progress of PT in the context 
of common infections encountered in ICUs and to de-
fine the challenges that need to be overcome in future 
laboratory and clinical trials.
BASICS OF PHAGE BIOLOGY
Phages are naturally occurring viruses that infect 
and lyse bacteria. Phages are ubiquitous, diverse, and 
thought to shape the composition of virtually all mi-
crobial niches. In humans, phages are present in many 
tissues and are particularly abundant in the gut (8). 
Bacterial surface molecules and phage receptor bind-
ing proteins determine an individual phages tropism 
(9). Some phages may have relatively broad bacte-
rial host ranges, capable of infecting strains from a 
few closely related species, whereas others may have 
narrow host ranges, limited to a few isolates within a 
single species.
Once adsorbed to the surface of a susceptible bacte-
rium, phage DNA is injected into the cell, at which point 
the phage can undergo two prototypical lifecycles; the 
lytic cycle, where phages propagate inside the bacteria, 
induces lysis and can then infect additional cells upon 
release, or the lysogenic cycle, where the phage genome 
is incorporated into that of the host bacteria (Fig. 1). 
“Temperate phages” can switch between the lysogenic 
and lytic lifecycles based on situational cues. The in-
tegration of temperate phages into bacterial genomes 
poses a threat for the transfer of potentially harmful 
genes (i.e., toxins and antibiotic resistance) between 
the strains, and as such, temperate phages are rarely 
considered for therapy. In contrast, “lytic phages” do 
not have the genetic capability to exercise a lysogenic 
cycle and are more appropriate for PT. Of note, early 
bacterial lysis can occur in the absence of phage rep-
lication (termed “lysis from without”) either when 
a large number of phage particles are absorbed onto 
the bacteria or as a consequence of the activity of ex-
ogenous phage products (10). In this context, phage-
encoded lysins are also currently being considered for 
therapeutic application (11).
PHAGES FOR THE TREATMENT OF 
ANTIBIOTIC-RESISTANT INFECTIONS
Antibiotics are relied upon not only to treat bacterial 
infections, but also to facilitate modern medical prac-
tices including invasive surgeries, organ transplan-
tations, and chemotherapy. Bacteria, however, have 
evolved to overcome antibiotics. The bacterial cell en-
velop is an imposing barrier that restricts the entry 
of toxic compounds. Antibiotics that penetrate can 
be extruded via resistance pumps, degraded or mod-
ified by specific enzymes, or lose activity due to muta-
tion/modification of the compounds target. Common 
sources of antibiotics were overmined midway 
through the 20th century, and recently, the antibiotic 
Figure 1. Prototypical phage lifecycles. Phages (red) recognize specific receptors on the surface of susceptible bacterial cells (blue). 
Following attachment, the phage genome is injected into the bacterial cell. Two prototypical phage lifecycles are illustrated. The lytic 
cycle involves phage replication, followed by cell lysis, liberating phages for subsequent infection. The lysogenic cycle involves integration 
of phage DNA into the bacterial chromosome. Lysogeny may facilitate the spread of harmful genes between bacteria. “Temperate 
phages” can switch between lysogenic and lytic cycles, and as such, they are not typically considered for therapy. “Lytic phages” can only 
use the lytic cycle and are more commonly used for phage therapy.
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development pipeline is running dry (12). Thus, there 
is an urgent need to develop alternative strategies to 
combat antibiotic-resistant bacterial infections.
Phages were first considered for therapy over 100 
years ago based on their ability to lyse bacterial cells 
(13) and have seen continued use in countries such as 
Georgia, Poland, and Russia (14, 15). Early clinical data 
about their efficacy were conflicting (16, 17) and often 
attributed to a poor understanding of fundamental 
phage biology. This, coupled with the early success of 
antibiotics saw phages, falls out of favor in most other 
countries. Phages, however, have characteristics that 
may be advantageous in the age of antibiotic resistance 
and equipped with an improved understanding of how 
they work, they warrant reconsideration. They enter 
and destroy bacterial cells using a mechanism that is 
distinct from traditional antibiotics, suggesting that 
the threat of phage-antibiotic cross-resistance is low. 
They may produce enzymes that can degrade biofilms 
(bacterial communities encased within a protective 
extracellular matrix) (18). Biofilms are notorious for 
challenging antibiotic therapy, particularly in the cases 
of foreign body infection. Phages replicate in the pres-
ence of susceptible bacteria (termed “autodosing”), 
which is desirable when considering PT for high bac-
terial load infections (19). Finally, they can be highly 
pathogen-specific, limiting the potential for off-target 
microbiome disruption, which has been associated 
with broad-spectrum antibiotic use (20) (Fig. 2).
PT is not without its own caveats. Most notably, PT 
may be complicated by “phage resistance,” where the 
therapeutic phage is unable to kill the target bacteria 
(akin to antibiotic resistance). Phage resistance may be 
intrinsic and present at the onset of therapy (4), or it 
may evolve during therapy (21). Bacteria may not have 
the appropriate surface receptor or may code for mo-
lecular systems that destroy phage DNA upon entry 
into the cell (i.e., clustered regularly interspaced short 
palindromic repeats-cas) (22) (Fig.  2). Importantly, 
phage resistance mechanisms are often highly specific; 
the emergence of resistance to one phage does not nec-
essarily result in resistance to a second, distinct phage. 
The sheer abundance and diversity of phages in nature 
should ensure that alternative phages are found to mit-
igate phage resistance (21). Additionally, “cocktails” 
consisting of a mixture of different phages are com-
monly used when treating patients.
In preparation for PT, phages should be genome-
sequenced to ensure that they are not temperate and 
do not code for harmful genes. The susceptibility of the 
infective bacteria to the phages should be confirmed 
in vitro, and the therapeutic product should be puri-
fied to eliminate residual bacterial components carried 
over from production (i.e., endotoxin) (23) (Fig. 3).
PHAGE THERAPY IN CRITICAL CARE 
SITUATIONS
Respiratory Tract Infections
Animal Reports. Pulmonary infections are an enor-
mous clinical challenge within the ICU (24). Using 
small animal models of respiratory infection, PT has 
consistently improved outcomes when compared with 
untreated controls (Table S1, http://links.lww.com/
CCX/A511). In an experimental model of ventilator-
associated pneumonia due to methicillin-resistant 
Staphylococcus aureus (MRSA), IV application of 
phages was as effective as standard-of-care antibiot-
ics (25). Local administration has also shown promise 
in the context of lung infection. Inhaled phages 
Figure 2. The pearls and perils of phage therapy. Phages have many beneficial characteristics to suggest they could be effective 
against antibiotic-resistant bacterial infections. Many obstacles, however, need to be circumvented in order for phage therapy to reach its 
clinical potential.
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controlled various Gram-negative bacteria (26–28), 
and nebulized phages, when applied prophylactically, 
rescued most animals from lethal MRSA pneumonia 
(29). Further studies are warranted to investigate the 
distribution of nebulized phages during ventilation 
and to determine their efficacy for the treatment of es-
tablished pneumonia.
Human Reports. PT for the treatment of pneumonia 
in humans has not been assessed in a randomized con-
trolled trial (RCT). However, recent case studies have 
shown promising results. Maddocks et al (30) reported 
successful eradication of multidrug-resistant (MDR) 
Pseudomonas aeruginosa. Initial treatment with anti-
biotics failed to result in clinical improvement. A 
7-day course of IV and nebulized phages used adjunct 
to antibiotics was associated with “remarkable” clin-
ical progress. Additional reports described infection 
resolution following adjunct PT for two ventilated 
patients with pneumonia, also due to MDR P. aeru-
ginosa (31), and a patient with lung infection due to 
MDR Klebsiella pneumoniae (32). Case reports have 
also described instances, where antibiotics and adjunct 
PT failed to resolve respiratory infections. In each case, 
therapy was complicated by phage resistance (31, 33). 
Nevertheless, preclinical and human case studies have 
reported largely positive findings, which suggest pneu-
monia is an appropriate setting for future RCTs assess-
ing the safety and efficacy of PT.
Abdominal Infections
Animal Reports. The abdomen is an important point 
of origin for sepsis and septic shock (1, 34). Abdominal 
infections are often due to vancomycin-resistant 
enterococci (VRE) and Gram-negatives including 
P. aeruginosa. In a rat model of abdominal infection 
caused by VRE, intraperitoneal injection of phages 
was as effective as antibiotics (ampicillin) in rescu-
ing animals from fatal sepsis. Importantly, PT did not 
appear to disrupt the gut microbiota (35). For P. aeru-
ginosa abdominal sepsis, orally administered phages 
improved survival, reduced organ bacterial densities, 
and alleviated inflammation compared with controls 
(36). Patients with severe abdominal infections in the 
ICU, however, will typically be administered therapeu-
tics IV, and this route is yet to be assessed using animal 
models.
Human Reports. Little is known about the useful-
ness of PT for life-threatening abdominal infections in 
humans; however, a recent case-report revealed posi-
tive patient outcomes (21). The case involved a criti-
cally ill patient with a pancreatic pseudocyst infected 
with MDR Acinetobacter baumannii that was refrac-
tory to antibiotic therapy. After 3 weeks of antibiotic 
and phage coadministration, the clinical condition 
improved resulting in extubation and discontinuation 
of vasopressor support. Phage resistance did emerge; 
however, its impact was mitigated by the rapid isola-
tion and purification of an additional phage from sew-
age, which was subsequently applied (21). Together, 
the case highlights the almost limitless pool of phages 
available in nature that may be useful for therapy, while 
illustrating the rapid nature with which bacteria can 
adapt to overcome them (Fig. 2).
Bloodstream Infections
Animal Reports. Most studies that evaluated PT for 
bloodstream infections in animal models revealed fa-
vorable outcomes with improved survival, reduced 
Figure 3. Preparing phages for therapy. Phages are ubiquitous and can be collected from a variety of sources including soil, natural 
water bodies, and sewage. Phages are first produced to high concentration within a susceptible bacterial host. Phages are then genome 
sequenced to exclude undesired genes (i.e., lysogeny, antibiotic resistance, and toxins). The susceptibility of the disease causing bacterial 
isolate should be tested by observing lysis plaques using double-layer agar plates or bacterial growth inhibition in liquid media. Prior to 
application, phage solutions should be purified to exclude potentially harmful bacterial debris (i.e., endotoxin).
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bacterial counts, and reduced inflammation when 
compared with untreated controls (Table S1, http://
links.lww.com/CCX/A511). Most studies lacked an 
antibiotic treatment control arm for comparison. 
Still, the few exceptions showed that phages per-
form at least as efficaciously as the standard-of-care 
(37–39).
Human Reports. Most, but not all of the recently 
published cases of compassionate use PT for blood-
stream infections reported a favorable outcome with 
either notable improvement of the clinical condition 
or infection resolution (32, 33, 40–42). All patients 
were severely ill and underwent unsuccessful antibi-
otic treatment prior to the start of PT. Typically, anti-
biotics were pursued concurrently with PT. A case 
series designed to assess safety and tolerability of PT 
in critically ill patients included patients with native 
or prosthetic valve endocarditis due to S. aureus (33). 
A positive effect was reported, reflected by a tendency 
toward improvement of clinical condition, lower in-
flammatory markers, and reduced bacterial counts. 
However, despite phage and antibiotic treatment, four 
patients succumbed to infection, likely reflecting the 
severity of underlying disease (33). A second case se-
ries presented three patients with aortic graft infec-
tions where PT adjunct to antibiotics controlled or 
eliminated the causative pathogens. For a fourth pa-
tient, local and systemic PT adjunct to IV daptomycin 
reduced S. aureus loads; however, the patient ulti-
mately succumbed to S. aureus sepsis (32).
Phages were typically applied IV (33, 41, 42), with 
additional examples using intracavitary (40), oral, 
and local intraoperative administration (32). Various 
treatment regimens have been used, from single in-
jection (40), to reapplication at regular intervals (33, 
42), and continuous infusion (41). However, the op-
timal approach remains unclear. Following IV injec-
tion, phages were detected in the circulation for up to 
12 hours and their number increased after repeated 
application, suggesting either phage autodosing, or 
a saturation mechanism in phage elimination (33). 
Elimination seems to be driven by the spleen, liver, and 
kidney (43); however, our understanding as to how 
phages are metabolized is incomplete.
In summary, data from animals and humans have 
shown that systemic PT seems safe, tolerable, and 
effective in combination with antibiotics at controlling 
bloodstream infections.
LESSONS FROM RECENT CLINICAL 
TRIALS
Much of the excitement surrounding PT for antibiotic-
resistant infections stems from human case reports. It is 
important, however, to maintain some degree of skepti-
cism; in most cases, patients remained on antibiotics, so 
the absolute impact of PT is unclear, and more gener-
ally, case reporting may be influenced by positive pub-
lication bias (i.e., failures are less likely to be published). 
In recent phase I/II randomized, placebo-controlled, 
double-blind clinical trials, the results are less prom-
ising. “PhagoBurn” (NCT02116010) assessed PT for se-
vere burn wound infections due to P. aeruginosa using 
a phage product designed to comply with good manu-
facturing and clinical practices (4). A phage-cocktail 
was delivered topically once daily for 7 days (n = 12) 
and compared with standard-of-care sulfadiazine silver 
(n = 13). The primary outcome was reduced bacterial 
growth on agar plates. Results of the trial were disap-
pointing; patients receiving PT took longer to reach the 
primary endpoint (144 vs 47 hr, p = 0.018), and fewer 
patients reached that end point by day 7, although 
this difference was not statistically significant (50% vs 
85%, p = 0.0917) (4). Intravesical phages were assessed 
for the treatment of urinary tract infections (UTIs; 
NCT03140085) (6). Instillation of phages into the blad-
der was not superior to instilled placebo, and although 
phages were not statistically inferior to antibiotics, the 
number of patients that reached the primary end point 
was lower at 7 days (5/28 for phages, 13/37 for antibi-
otics, p = 0.11). Finally, the largest RCT performed to 
date, investigating oral PT for diarrhea in children due 
to Escherichia coli (NCT00937274), was stopped fol-
lowing an interim analysis (120 of 375 patients), citing 
“no amelioration in quantitative diarrhea” (5).
These trials illustrated some of the shortcomings for 
the clinical application of PT. Although these safety-
driven RCTs may have been underpowered to reveal 
treatment efficacy outcomes, it is apparent that posi-
tive results from preclinical trials have so far failed to 
translate to positive patient outcomes (Fig. 4). In the 
context of PhagoBurn, topically applied phages were 
statistically superior to standard-of-care (silver nitrate) 
in a murine model of P. aeruginosa burn wound in-
fection (44), which is juxtaposed to the findings of the 
trial. Additionally, the stability of the therapeutic was 
poor, which contradicted laboratory findings, meaning 
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patients received ~10,000 times fewer phages than was 
intended. Although the occurrence of adverse events 
was not different between the treatments hinting to-
ward safety, the importance of this finding was con-
founded by the use of low doses (4).For the treatment 
of UTI, phages were instilled into the bladder to reduce 
the potential systemic effects of PT, yet, to our know-
ledge, this treatment approach had not been explored 
in experimental studies, which may represent a dis-
connect in the progression from “bench-to-bedside” 
(Fig. 4). The authors hypothesized that mechanical ir-
rigation of the bladder may have explained any ther-
apeutic effects based on the similar efficacy of each 
treatment arm to placebo (6). The high rate of sponta-
neous clearance (~30%) may indicate that the infection 
setting is not ideal for the assessment of PT.Finally, the 
nature of the therapeutic product is highly important. 
PhagoBurn tested a predefined cocktail of 12 phages 
that were designed to cover a wide range of P. aeru-
ginosa clinical isolates. However, susceptibility to the 
cocktail was not tested prior to randomization, and 
treatment failures were attributed largely to “inter-
mediate resistance” at the start of therapy. Similarly, 
only half of the patients from the E. coli diarrhea trial 
had phage-susceptible E. coli in their stool (5). In con-
trast, for the UTI trial, phage sensitivity was confirmed 
in vitro before assigning patients to the phage treat-
ment arm, which is a clinically important approach. 
However, the exact concentration and composition 
of the phage product were not described, which, if 
known, may have helped to explain the poor efficacy of 
PT, as data from animal models of UTI have revealed 
phage dose-dependencies (45).At the very least, these 
foundational RCTs have highlighted some of the hur-
dles, both biological and regulatory, that need to be 
circumvented in future trials.
BLUEPRINT FOR PHAGE THERAPY IN 
THE ICU
The acute nature of many ICU infections presents 
a unique set of challenges for the application of PT. 
In chronic settings, there is sufficient time to tailor a 
personalized treatment. This may include a hunt for 
efficient phages in the environment and global phage 
biobanks, or engineering of phages for improved infec-
tivity and persistence (46–48). In contrast, the window 
of time is considerably narrower for patients in the 
ICU. Thus, an appropriate PT treatment algorithm will 
need to be designed to be executed rapidly. In order to 
implement PT within days of a diagnosis, centralized 
facilities will likely need to maintain ready-to-use phage 
preparations. Although this approach proved challeng-
ing in the PhagoBurn RCT, the process would benefit 
from a better understanding of phage storage and dis-
tribution requirements and the generation of improved 
phage cocktails that are broadly effective in the con-
text of local infection epidemiology. Alternatively, the 
increased use of whole genome sequencing in routine 
clinical microbiology has paved the way for computa-
tional approaches to predict positive pathogen-phage 
interactions (49). Once PT is initiated, its effectiveness 
should be continually monitored to ensure that phage 
resistance does not emerge. This will require the estab-
lishment of standardized definitions of resistance, akin 
to minimum inhibitory concentration breakpoints for 
antibiotics, and protocols that can be easily adopted by 
diagnostic microbiology laboratories.
Even when facing the current antibiotic resistance 
crisis, antibiotics remain a cornerstone of critical care. It 
is unlikely that clinicians will cease antibiotics altogether 
in favor of PT, even if the infection is responding poorly 
to the standard-of-care. Indeed, all bar one human case 
Figure 4. The “bench-to-bedside” nature of the evidence to support the implementation of phage therapy.
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study has seen PT applied as an adjunct to multiple an-
tibiotic classes (Table S1, http://links.lww.com/CCX/
A511). It is then surprising that most preclinical stud-
ies and each of the RCTs detailed above did not assess 
phage-antibiotic combination therapies. When tested at 
different concentrations in vitro, some phage-antibiotic 
combinations can reveal synergisms (50, 51), additive 
effects, and, most worryingly, antagonisms (50), which 
may ultimately reduce treatment efficacy. These impor-
tant findings should be further assessed in vivo to avoid 
antagonisms and exploit synergies.
Phage dosing and timing are each crucial for effec-
tive PT. Insufficient phage concentrations and delays 
in the initiation of treatment have been consistently 
associated with poor outcomes (38, 52–59). However, 
the available data do not yet point to clear answers as 
to how phages should be administered and how fre-
quently this should occur. For the former, IV applica-
tion of phages seems safe and should not be shied away 
from in future trials, and nebulized phages applied to 
mechanically ventilated subjects warrant future inves-
tigation (29, 30). For the latter, phage pharmacokinetic 
and pharmacodynamic (PK/PD) models need to be 
developed (60) and tested to systematically determine 
optimal phage dosing strategies.
CONCLUSIONS
Recent RCTs assessing PT failed to demonstrate effi-
cacy in humans. Future success requires a concerted 
effort by the research community to perform further 
studies to overcome phage resistance, exploit phage-
antibiotic synergies, and to optimize phage PK/PD.
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